UK markets close in 1 hour 1 minute

Mereo BioPharma Group plc (MREO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
0.5200+0.0300 (+6.12%)
As of 10:27AM EDT. Market open.
Full screen
Loading interactive chart…
  • Globe Newswire

    Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

    LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company’s Board of Directors, effective immediately. Dr. Mullick joins Mereo’s Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geogr

  • Globe Newswire

    Mereo BioPharma announces Positive Top-Line Efficacy and Safety Data from “ASTRAEUS” Phase 2 Trial of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema

    Statistically significant inhibition of blood neutrophil elastase activity of up to 90% in patients in both high and low dose alvelestat groups throughout the 12-week dosing period Statistically significant reductions in the biomarkers Aα-val360 and desmosine at the high dose demonstrating clear impact of alvelestat on the pathogenic pathway of AATD-lung disease No safety signals were associated with alvelestat Conference Call Today at 10:30 a.m. ET LONDON and REDWOOD CITY, Calif., May 09, 2022

  • Globe Newswire

    Mereo BioPharma to Host Conference Call Highlighting Top-line Clinical Data from “ASTRAEUS” Phase 2 Study of Alvelestat

    Call scheduled for Monday, May 9, 2022 at 10:30 a.m. ETLONDON and REDWOOD CITY, Calif., May 06, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced it will host a conference call on Monday, May 9, 2022 at 10:30 a.m. ET to review top-line clinical data from its “ASTRAEUS” Phase 2 Study of Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Emphysema. Confe